title: Ability of orally administered IFN-α4 to inhibit naturally occurring gingival inflammation in dogs.
abstract: It has been reported that type I interferons (IFN-α/β) play an important role in innate immune responses against viral and bacterial infections. In this study, we used and examined naturally occurred canine periodontal disease to show the therapeutic efficacy of low dose oral administration (LDOA) of canine IFN-α subtype 4 (CaIFN-α4). We administered purified recombinant CaIFN-α4 expressed in a baculovirus system to dogs with or without gingival inflammation. We found that LDOA of CaIFN-α4 reduce periodontopathic bacterial counts. LDOA induced improvement of naturally occurring gingival inflammation, and reduction of the stress marker responses was also observed after LDOA. These results suggest that LDOA of CaIFN-α4 has effectiveness for improvement of naturally occurring gingival inflammation in dogs.
authors.affiliation: Research Institute of Genome-Based Biofactory, National Institute of Advanced Industrial and Science Technology (AIST), Sapporo, Hokkaido, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Ito
authors.forename: Emiko
authors.initials: E
authors.lastname: Isogai
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Yoshioka
authors.forename: Ko
authors.initials: K
authors.lastname: Sato
authors.forename: Naomi
authors.initials: N
authors.lastname: Himeno
authors.forename: Toru
authors.initials: T
authors.lastname: Gotanda
mesh_terms: D000080242:8-Hydroxy-2'-Deoxyguanosine; D000284:Administration, Oral; D000818:Animals; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000032:analysis; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005891:Gingivitis / Q000188:drug therapy / Q000662:veterinary*; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D018384:Oxidative Stress / Q000187:drug effects; D010510:Periodontal Diseases / Q000188:drug therapy / Q000662:veterinary*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012463:Saliva / Q000378:metabolism; D014779:Virus Replication / Q000187:drug effects
chemical_list: D016898:Interferon-alpha; D011994:Recombinant Proteins; D000080242:8-Hydroxy-2'-Deoxyguanosine; D003849:Deoxyguanosine